[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US10925918B2 - Composition for food and fat absorption inhibitor - Google Patents

Composition for food and fat absorption inhibitor Download PDF

Info

Publication number
US10925918B2
US10925918B2 US14/601,362 US201514601362A US10925918B2 US 10925918 B2 US10925918 B2 US 10925918B2 US 201514601362 A US201514601362 A US 201514601362A US 10925918 B2 US10925918 B2 US 10925918B2
Authority
US
United States
Prior art keywords
extract
fat absorption
seaweed
plant
polyphenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/601,362
Other versions
US20150132338A1 (en
Inventor
Yuriko Oda
Fumitaka Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Assigned to FUJIFILM CORPORATION reassignment FUJIFILM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ODA, YURIKO, UEDA, FUMITAKA
Publication of US20150132338A1 publication Critical patent/US20150132338A1/en
Application granted granted Critical
Publication of US10925918B2 publication Critical patent/US10925918B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A23F3/18—Extraction of water soluble tea constituents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A23L17/60—Edible seaweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/214—Tea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for food and a fat absorption inhibitor.
  • WO 2007/125644 discloses a composition for inhibiting fat absorption that includes a mixture of four components—theaflavin monogallate, a theaflavin, theaflavin digallate, and polyphenol.
  • JP-A Japanese Patent Application Laid-Open (JP-A) No. 2005-170836 discloses a lipase inhibitor that includes, as an active ingredient, an extract of Ascophyllum nodosum , which is a brown algae corresponding to one type of marine algae.
  • the extract of Ascophyllum nodosum is a component referred to as “seaweed polyphenol” and has a favorable lipase inhibitory activity.
  • compositions having an fat absorption inhibitory effect that does not deteriorate the intestinal environment are not known.
  • the present invention addresses provision of a composition for food and a fat absorption inhibitor that can effectively inhibit fat absorption without deteriorating the intestinal environment.
  • composition for food a fat absorption inhibitor, and a method of inhibiting fat absorption as described below are provided.
  • a composition for food including a seaweed polyphenol and a tea extract.
  • composition for food according to [1] further including an extract of a plant of the genus Salacia.
  • composition for food according to any one of [1] to [5], which is in tablet form or capsule form.
  • composition for food according to any one of [1] to [7], in which a ratio (mass ratio) of the tea extract to the seaweed polyphenol is from 100 to 0.01.
  • a fat absorption inhibitor including a seaweed polyphenol and a tea extract.
  • a method of inhibiting fat absorption including administrating the fat absorption inhibitor according to any one of [9] to [16] to a subject in need of inhibition of fat absorption.
  • composition for food and fat absorption inhibitor that can effectively inhibit fat absorption without deteriorating the intestinal environment can be provided.
  • composition for food according to the invention is a composition for food including a seaweed polyphenol and a tea extract.
  • a seaweed polyphenol ingested inhibits fat absorption due to the fat absorption inhibitory effect of the seaweed polyphenol, as a result of which fat accumulates in the intestine.
  • the accumulation results in proliferation of harmful intestinal bacteria (e.g., bacteria of the genus Clostridium , bacteria of the genus Enterobacter ) and the like.
  • the harmful intestinal bacteria produce gas, which cause sensation of abdominal bloating.
  • the proliferation of the harmful intestinal bacteria reduces bowel movement and thus deterioratess the intestinal environment.
  • the tea extract can alleviate the sensation of abdominal bloating and improve the bowel movement.
  • the invention is not constrained by such presumption.
  • process indicates not only a separate process but also a process that is not clearly distinguished from other processes as long as the desired effect of the process is obtained therefrom.
  • each numerical range specified using “(from) . . . to . . . ” represents a range including the numerical values noted before and after “to” as the minimum value and the maximum value, respectively.
  • the amount of each ingredient in the composition when the composition includes plural substances corresponding to a particular ingredient, the amount of the particular ingredient noted in this specification means the total amount of the plural substances in the composition unless otherwise specified.
  • the seaweed polyphenol is used as a generic name for a polyphenol extracted from a seaweed or a polyphenol-containing fraction extracted from a seaweed, and the seaweed polyphenol includes a phlorotannin compound (e.g., phloroglucinol or a polymer thereof) as a main component.
  • the seaweed polyphenol is preferably a brown algae-derived polyphenol. Examples of the brown algae include brown seaweeds of the genus Ascophyllum, Laminaria, Sargassum, Eisenia bicyclis, Ecklonia cava , and Ecklonia kurome . From the viewpoint of the fat absorption inhibitory effect, the brown algae is preferably a seaweed of the genus Ascophyllum , particularly Ascophyllum nodosum.
  • an extraction solvent that may be used for extracting the seaweed polyphenol, water or an organic solvent, or a mixed solution thereof is used.
  • the organic solvent include polar organic solvents including lower alcohols having from 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, sec-butanol, and tert-butanol, and ketones such as dimethyl ketone, methyl ethyl ketone, acetone, and methyl isobutyl ketone; and non-polar organic solvents such as methyl acetate, ethyl acetate, butyl acetate, and diethyl ether.
  • a mixed product obtained by appropriately combining a polar organic solvent, such as those described above, and a non-polar organic solvent, such as those described above, is also usable.
  • extraction methods usable for obtaining the extract include known methods such as immersion extraction, heat extraction, continuous extraction, and supercritical extraction.
  • the extract may subsequently be concentrated using known methods.
  • the obtained extract, concentrate or the like may be further purified using known methods.
  • purification methods include ultrafiltration, adsorption resin treatment, molecule chromatography, partition chromatography, and liquid-liquid extraction.
  • it is preferable that the seaweed polyphenol has a lipase inhibitory activity.
  • methods usable for preparation of the seaweed polyphenol include the method described in paragraphs [0017], [0018], and [0021] of JP-A No. 2005-170836.
  • the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC 50 value) against lipase of preferably from 0.0001 ⁇ g/ml to 50 ⁇ g/ml, and more preferably from 0.001 ⁇ g/ml to 10 ⁇ g/ml.
  • IC 50 value inhibitory concentration against lipase
  • the half-maximal (50%) inhibitory concentration against lipase may be measured, for example, according to the method described in paragraph [0019] of JP-A No. 2005-170836.
  • the IC 50 value of the seaweed polyphenol against lipase may vary according to, for example, the method employed for extracting the extract.
  • seaweed polyphenol in the invention a commercially available product with a desired half-maximal (50%) inhibitory concentration against lipase may be used, as appropriate.
  • the commercially available product include “Seaweed Polyphenol” (derived from Ascophyllum nodosum , RIKEN VITAMIN Co., Ltd.).
  • the content of seaweed polyphenol in the composition for food varies according to the dosage form or the administration manner of the composition for food.
  • the content of seaweed polyphenol in the composition for food is not particularly limited as long as the amount is effective in inhibiting fat absorption.
  • the content of seaweed polyphenol in the composition for food may be set to be, for example, from 0.00001% by mass to 10% by mass, and preferably from 0.00001% by mass to 5% by mass, with respect to the total mass of the composition.
  • the content of seaweed polyphenol in the composition for food may be set to be, for example, from 0.001% by mass to 50% by mass, preferably from 0.01% by mass to 20% by mass, and more preferably from 0.1% by mass to 5% by mass, with respect to the total mass of the composition.
  • the dose of the composition for food is not particularly limited and varies according to the dosage form or the like. In general, the dose of the composition for food in the case of single daily dosing may be from 1 mg to 500 mg, and preferably from 5 mg to 200 mg, in terms of the seaweed polyphenol dose.
  • the tea extract in the invention is an extract obtained from a tea plant, which is an evergreen tree of the Theaceae family.
  • a tea plant which is an evergreen tree of the Theaceae family.
  • the tea extract is preferably a green tea extract from the viewpoint of the effect with respect to improvement of the intestinal environment.
  • the extraction of the tea extract is preferably conducted using water, alcohol, or a hydrous alcohol as an extraction solvent.
  • the extraction solvent to be used is more preferably hot water, ethanol, or hydrous ethanol.
  • the alcohol concentration in the hydrous alcohol may be set to be from 30% by mass to 90% by mass, and preferably from 40% by mass to 70% by mass, with respect to the total mass of the hydrous alcohol. Examples of methods usable for drying include, but not limited to, spray drying and freeze drying.
  • the tea extract preferably includes an antioxidative substance such as a polyphenol or a catechin. More specifically, the tea extract preferably inclures catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, or epigallocatechin gallate, or a combination of two or more thereof, and more preferably includes epigallocatechin gallate.
  • the content of tea extract in the composition for food varies according to the dosage form or the administration manner of the composition for food, and is not particularly limited.
  • the content of tea extract in the composition for food may be any content which can improve the intestinal environment in relation to the seaweed polyphenol.
  • the content of tea extract in the composition for food may be set to 0.0001% by mass to 20% by mass, and preferably 0.001% by mass to 10% by mass, with respect to the total mass of the composition.
  • the content of tea extract in the composition for food may be set to be from 0.5% by mass to 80% by mass, preferably from 1% by mass to 70% by mass, and more preferably from 5% by mass to 30% by mass, with respect to the total mass of the composition.
  • the ratio of tea extract to seaweed polyphenol may vary according to the levels of concentration of the respective components.
  • the ratio of tea extract/seaweed polyphenol in the composition for food may be set to be preferably from 100 to 0.01, more preferably from 80 to 0.05, still more preferably from 50 to 3, and even more preferably from 15 to 3.
  • the tea extract/seaweed polyphenol ratio in the composition for food is set to be 0.01 or more, a more favorable effect with respect to improvement of the intestinal environment can be produced.
  • composition for food according to the invention may further include an extract of a plant of the genus Salacia .
  • composition for food further includes an extract of a plant of the genus Salacia , further improvement of the intestinal environment, including bowel movement improvement and/or fecal properties, can be achieved.
  • the plant of the genus Salacia is a plant of Celastraceae that grows wild mainly in Sri Lanka, India, and south-eastern Asia, and the plant is more specifically at least one plant selected from the group consisting of Salacia reticulata, Salacia oblonga, Salacia prinoides , and Salacia chinensis .
  • Examples of the extract of a plant of the genus Salacia that may be contained in the composition for food include an extract obtained by extraction from a pulverized product of the whole plant body of a plant of the genus Salacia , and an extract (preferably, an extract powder) obtained from a portion, such as a root, a trunk, a leaf, a flower or a fruit, of the plant. It is also contemplated that one or more portions of the plant may be mixed and used.
  • the extract of a plant of the genus Salacia for use is more preferably an extract obtained by extraction from a root or a trunk.
  • the extract is preferably an extract obtained by drying a product which in turn is obtained from the whole plant or any of the portions of the plant by extraction with a solvent.
  • the extraction solvent may be selected from water, an alcohol such as methanol or ethanol, or a mixed solvent of water with an alcohol or ketone such as acetone.
  • the extraction solvent to be used is preferably water, an alcohol, or a hydrous alcohol.
  • the extraction solvent to be used is more preferably hot water, ethanol, or hydrous ethanol.
  • the alcohol concentration in the hydrous alcohol may be set to be from 30% v/v to 90% v/v, and preferably from 40% v/v to 70% v/v. Examples of drying methods include, but not limited to, spray drying and freeze drying.
  • the extract of a plant of the genus Salacia according to the invention preferably has a half-maximal (50%) inhibitory concentration (IC 50 value) against sucrase of 2,000 ⁇ g/ml or less.
  • IC 50 value inhibitory concentration
  • a half-maximal (50%) inhibitory concentration of the extract of a plant of the genus Salacia against sucrase of 2,000 ⁇ g/ml or less ensures an increase in the number of beneficial intestinal bacteria such as bacteria of the genus Bifidobacterium (sometimes simply referred to as “bifidobacteria”), and enables the intestinal environment to be more improved.
  • the half-maximal (50%) inhibitory concentration against sucrase may be set to be preferably from 0.001 ⁇ g/ml to 1,500 ⁇ g/ml, more preferably from 0.05 ⁇ g/ml to 1,000 ⁇ g/ml, and still more preferably from 0.05 ⁇ g/ml to 800 ⁇ g/ml.
  • the half-maximal (50%) inhibitory concentration against sucrase may be measured according to the method described in paragraphs [0009] to [0012] of JP-A No. 2009-249315.
  • composition for food according to the invention may further include a component, other than the above-described components, that can improve the intestinal environment.
  • a component other than the above-described components, that can improve the intestinal environment.
  • the component that improves the intestinal environment include yoghurt and oligosaccharide.
  • the composition for food according to the invention may further include at least one selected from the group consisting of calcium carbonate and silicon dioxide.
  • the inclusion of such a substance can prevent discoloration over time of components contained in the composition for food.
  • the composition for food contains an extract of a plant of the genus Salacia
  • the inclusion can prevent discoloration over time of the extract of a plant of the genus Salacia .
  • the silicon dioxide is preferably fine silicone dioxide in powder form.
  • the content of calcium carbonate or silicon dioxide in the composition varies according to the dosage form of the composition.
  • the content of calcium carbonate is preferably from 0.1% by mass to 10% by mass with respect to the composition
  • the content of silicon dioxide is preferably from 0.5% by mass to 20% by mass with respect to the composition.
  • calcium carbonate and silicon dioxide are used in combination, they may be used at a ratio of calcium carbonate to silicon dioxide in a range of from 1:0.05 to 1:200 in terms of mass ratio.
  • composition for food according to the invention may include, besides the above-described components, a carrier acceptable for food applications or a publicly-known or well-known additive agent.
  • Examples of a carrier preferably used for formulating the composition to have a solution form include aqueous media such as water.
  • examples of an additive preferably used for formulating the composition to have a solid form include excipients such as crystalline cellulose and magnesium stearate, and swelling agents such as cornstarch and alginic acid.
  • shellac, sugar, a film coating base material, Yeast wrap or the like may be used as a coating agent for tablets, capsules, or granules.
  • low hygroscopic raw materials and moisture absorbents usable as foods or food additives may be used.
  • Preferable examples of usable low hygroscopic raw materials include cellulose, crystalline cellulose, cellulose powder, microcrystalline cellulose, lactose, a sugar alcohol, trehalose, magnesium stearate, and calcium stearate.
  • Examples of usable moisture absorbents include silicates, magnesium carbonate, ferrocyanides, and polysaccharides.
  • More preferable examples of usable low hygroscopic raw materials include crystalline cellulose, microcrystalline cellulose, and lactose, and a combination of two or more thereof.
  • Examples of a compound required for shaping into a powder form, a solid form, or a liquid form include erythritol, maltitol, hydroxypropylcellulose, kaolin, and talc.
  • a black oolong tea polyphenol, an onion peel extract, a red wine polyphenol, a coffee bean manno-oligosaccharide, Orlistat, a star fruit extract, a wheat extract or the like may further be used as another fat absorption inhibiting component.
  • composition for food according to the invention may be formulated into any of the liquid, solid, powder, and gel forms, and may be formulated into a form such as a solution, a tablet, a capsule (hard capsule, soft capsule) or a granule. It is preferable to formulate the composition for food into a tablet or a capsule from the viewpoint of convenience in use.
  • the fat absorption inhibitor according to the invention includes a seaweed polyphenol and a tea extract. Due to the combined inclusion of a seaweed polyphenol and a tea extract, the fat absorption inhibitor can inhibit fat absorption without deteriorating the intestinal environment, as descried above.
  • the fat absorption inhibitor may further include an extract of a plant of the genus Salacia . The inclusion of an extract of a plant of the genus Salacia enables improvement of bowel movement, fecal properties, and the like.
  • the manner of administering the fat absorption inhibitor according to the invention is preferably oral administration, but may be parenteral administration such as rectal administration or sublingual administration.
  • a method of inhibiting fat absorption which includes administrating a fat absorption inhibitor that includes a seaweed polyphenol and a tea extract to a subject in need of inhibition of fat absorption.
  • a fat absorption inhibitor that includes a seaweed polyphenol and a tea extract
  • the absorption of fat into the body can be inhibited without deteriorating the intestinal environment.
  • the subject to which the fat absorption inhibitor is administered include a mammal such as human.
  • use of a seaweed polyphenol and a tea extract in the manufacture of a fat absorption inhibitor and use of a seaweed polyphenol, a tea extract, and an extract of a plant of the genus Salacia in the manufacture of a fat absorption inhibitor, are also provided.
  • composition for food and the fat absorption inhibitor according to the invention can inhibit fat absorption without deteriorating the intestinal environment. Therefore, the composition for food and the fat absorption inhibitor are expected to ameliorate life-style related diseases or obesity, and to exert effect with respect to the prevention or treatment of various symptoms or diseases associated with aging. Furthermore, the composition for food and the fat absorption inhibitor are expected to also exert effects with respect to weight loss, a decrease in body fat percentage, or the like.
  • Example 1 to 4 40 male adults (from age 20 to age 60) were randomly divided into 8 groups each consisting of 5 people.
  • Ingestion test was carried out for one week with respect to the samples designated for the respective groups (Examples 1 to 4 and Comparative Examples 1 to 4). The ingestion was performed by dividing the following one-day dose into three doses and having this ingested. After the intake of the sample, the questionnaire survey on abdominal symptom and fecal properties was carried out. The results are shown in Table 1. In the table, the number of the blend ratio of each component represents a percentage by mass. Here, the amount of the seaweed polyphenol ingested per day was set to 20 mg.
  • Seaweed polyphenol a product manufactured by RIKEN VITAMIN Co., Ltd., having an IC 50 value against lipase of 0.01 ⁇ g/ml or less
  • Green tea extract a commercial product
  • Extract of a plant of the genus Salacia a Salacia reticulata extract having an IC 50 value against sucrase of 200 ⁇ g/ml or less
  • IC 50 value of the extract of a plant of the genus Salacia against sucrase and IC 50 value of each sample against lipase were determined as follows.
  • sample solution 2 mg of the extract of the plant of the genus Salacia was weighed out and put in a tube. 2 mL of water was added thereto, and the resultant mixture was thoroughly suspended to prepare a sample solution having a concentration of 1 mg/mL. The obtained sample solution was diluted with water to varied concentrations of 0, 50, 100, 250, and 500 ⁇ g/mL.
  • sucrose was dissolved in a 0.2 M maleate buffer (pH 6.0) to a sucrose concentration of 100 mM, and the resultant solution was used as a substrate solution.
  • the substrate solution 400 ⁇ L was added to 500 ⁇ L each of the above-described sample solutions having the varied concentrations, and the solutions were pre-heated in a water bath at 37° C. for 5 minutes.
  • 100 ⁇ L of the crude enzyme solution was added to each of the solutions, and a reaction was allowed to proceed at 37° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated by heating at 95° C. for 2 minutes, thereby terminating the reaction.
  • the concentration of glucose produced was quantitatively determined using a commercially available GLUCOSE CII TEST WAKO kit based on the mutarotase glucose oxidase method (Wako Pure Chemical Industries, Ltd).
  • Preparation of blank To 250 ⁇ L each of the above-described sample solutions having the varied concentrations, 200 ⁇ L of the substrate solution and 50 ⁇ L of the crude enzyme solution were added, and the solutions were heated at 95° C. for 2 minutes immediately after the addition of the crude enzyme solution, thereby thermally inactivating the enzyme and obtaining blank data. A calibration curve was obtained based on the obtained values, and a concentration at which the enzyme activity is inhibited by 50% (IC 50 value) was determined.
  • sample solution 2 mg of the composition for food (Examples 1 to 4, Comparative Examples 1 to 4) was weighed out and put in a tube. 2 mL of water was added thereto, and the resultant mixture was thoroughly suspended to prepare a sample solution having a concentration of 1 mg/mL. The obtained sample solution was diluted with water to varied concentrations of 0, 50, 100, 250, and 500 ⁇ g/mL.
  • Lipase from porcine pancreas was diluted with ultrapure water to prepare a solution having a concentration of 0.1 mg/mL.
  • Preparation of measurement sample 10 ⁇ L of the lipase solution was added to 100 ⁇ L of the sample solution, followed by thorough mixing.
  • Lipase inhibitory activity was quantified using a LIPASE KIT S (DS Pharma Biomedical Co., Ltd.).
  • the IC 50 values of the obtained samples against lipase are indicated in Table 1 as relative values with the IC 50 value of Comparative Example 1 being designated as 1.
  • the values regarding the abdominal symptom and the fecal properties based on the results of questionnaire survey are as follows.
  • sensation of abdominal bloating average of evaluations made by five people with respect to the following:
  • fat absorption can be inhibited without deteriorating the intestinal environment.
  • Samples of the extract of the plant of the genus Salacia having half-maximal (50%) inhibitory concentrations (IC 50 values) against sucrase ranging from 0 ⁇ g/ml to 2,000 ⁇ g/ml were prepared by appropriately mixing the extract of the plant of the genus Salacia (extract powder) and a crystalline cellulose.
  • the extract of the plant of the genus Salacia used in Example 2 may be used as an extract of a plant of the genus Salacia
  • the seaweed polyphenol used in Example 1 may be used as seaweed polyphenol.
  • the capsule formulation is obtained by filling a filling composition that includes the components as listed in the following formulation into the interior of a gelatin capsule film, using a conventional method.
  • compositions for food enables inhibition of fat absorption without deterioration of the intestinal environment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition for food and a fat absorption inhibitor, each including a seaweed polyphenol and a tea extract.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of International Application No. PCT/JP2013/072603, filed Aug. 23, 2013, the disclosure of which is incorporated herein by reference in its entirety. Further, this application claims priority from Japanese Patent Application No. 2012-211331, filed Sep. 25, 2012, the disclosure of which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention relates to a composition for food and a fat absorption inhibitor.
BACKGROUND ART
In recent years, an environment is provided in which excessive fat ingestion easily occurs due to dietary life centered on high fat food introduced by westernization of diet. For this reason, drugs or food materials that inhibit fat absorption have attracted attention.
For example, International Publication No. WO 2007/125644 discloses a composition for inhibiting fat absorption that includes a mixture of four components—theaflavin monogallate, a theaflavin, theaflavin digallate, and polyphenol.
Japanese Patent Application Laid-Open (JP-A) No. 2005-170836 discloses a lipase inhibitor that includes, as an active ingredient, an extract of Ascophyllum nodosum, which is a brown algae corresponding to one type of marine algae.
In particular, it is known that the extract of Ascophyllum nodosum is a component referred to as “seaweed polyphenol” and has a favorable lipase inhibitory activity.
SUMMARY OF INVENTION Technical Problem
However, the inventors of the present application found that intake of a composition or component having an fat absorption inhibitory effect as a food material deteriorates the intestinal environment. Compositions having a fat absorption inhibitory effect that does not deteriorate the intestinal environment are not known.
Therefore, the present invention addresses provision of a composition for food and a fat absorption inhibitor that can effectively inhibit fat absorption without deteriorating the intestinal environment.
Solution to Problem
According to aspects of the invention, a composition for food, a fat absorption inhibitor, and a method of inhibiting fat absorption as described below are provided.
[1] A composition for food including a seaweed polyphenol and a tea extract.
[2] The composition for food according to [1], further including an extract of a plant of the genus Salacia.
[3] The composition for food according to [2], in which the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 2000 μg/ml or less.
[4] The composition for food according to any one of [1] to [3], in which the seaweed polyphenol is a brown algae-derived polyphenol.
[5] The composition for food according to any one of [1] to [4], in which the tea extract is a green tea extract.
[6] The composition for food according to any one of [1] to [5], which is in tablet form or capsule form.
[7] The composition for food according to any one of [1] to [6], in which the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of from 0.0001 μg/ml to 50 μg/ml.
[8] The composition for food according to any one of [1] to [7], in which a ratio (mass ratio) of the tea extract to the seaweed polyphenol is from 100 to 0.01.
[9] A fat absorption inhibitor including a seaweed polyphenol and a tea extract.
[10] The fat absorption inhibitor according to [9], further including an extract of a plant of the genus Salacia.
[11] The fat absorption inhibitor according to [10], in which the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 2000 μg/ml or less.
[12] The fat absorption inhibitor according to any one of [9] to [11], in which the seaweed polyphenol is a brown algae-derived polyphenol.
[13] The fat absorption inhibitor according to any one of [9] to [12], in which the tea extract is a green tea extract.
[14] The fat absorption inhibitor according to any one of [9] to [13], which is in tablet form or capsule form.
[15] The fat absorption inhibitor according to any one of [9] to [14], in which the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of from 0.0001 μg/ml to 50 μg/ml.
[16] The fat absorption inhibitor according to any one of [9] to [15], in which a ratio (mass ratio) of the tea extract to the seaweed polyphenol is from 100 to 0.01.
[17] A method of inhibiting fat absorption, the method including administrating the fat absorption inhibitor according to any one of [9] to [16] to a subject in need of inhibition of fat absorption.
[18] Use of a seaweed polyphenol and a tea extract in the manufacture of a fat absorption inhibitor.
[19] Use of a seaweed polyphenol, a tea extract, and an extract of a plant of the genus Salacia in the manufacture of a fat absorption inhibitor.
[20] The use in the manufacture of the fat absorption inhibitor according to [18] or [19], in which the seaweed polyphenol is a brown algae-derived seaweed polyphenol.
Advantageous Effects of Invention
According to the invention, a composition for food and fat absorption inhibitor that can effectively inhibit fat absorption without deteriorating the intestinal environment can be provided.
DESCRIPTION OF EMBODIMENTS
The composition for food according to the invention is a composition for food including a seaweed polyphenol and a tea extract.
In the composition for food according to the invention, inclusion of a seaweed polyphenol and a tea extract enables effective inhibition of fat absorption without deteriorating the intestinal environment. We presume that the reason therefor is as follows. Specifically, a seaweed polyphenol ingested inhibits fat absorption due to the fat absorption inhibitory effect of the seaweed polyphenol, as a result of which fat accumulates in the intestine. The accumulation in turn results in proliferation of harmful intestinal bacteria (e.g., bacteria of the genus Clostridium, bacteria of the genus Enterobacter) and the like. The harmful intestinal bacteria produce gas, which cause sensation of abdominal bloating. Furthermore, the proliferation of the harmful intestinal bacteria reduces bowel movement and thus deterioratess the intestinal environment. The tea extract can alleviate the sensation of abdominal bloating and improve the bowel movement. However, the invention is not constrained by such presumption.
The term “process” as used herein indicates not only a separate process but also a process that is not clearly distinguished from other processes as long as the desired effect of the process is obtained therefrom.
In this specification, each numerical range specified using “(from) . . . to . . . ” represents a range including the numerical values noted before and after “to” as the minimum value and the maximum value, respectively.
Furthermore, in reference to the amount of each ingredient in the composition, when the composition includes plural substances corresponding to a particular ingredient, the amount of the particular ingredient noted in this specification means the total amount of the plural substances in the composition unless otherwise specified.
Hereinbelow, the invention is described in detail.
In the invention, the seaweed polyphenol is used as a generic name for a polyphenol extracted from a seaweed or a polyphenol-containing fraction extracted from a seaweed, and the seaweed polyphenol includes a phlorotannin compound (e.g., phloroglucinol or a polymer thereof) as a main component. The seaweed polyphenol is preferably a brown algae-derived polyphenol. Examples of the brown algae include brown seaweeds of the genus Ascophyllum, Laminaria, Sargassum, Eisenia bicyclis, Ecklonia cava, and Ecklonia kurome. From the viewpoint of the fat absorption inhibitory effect, the brown algae is preferably a seaweed of the genus Ascophyllum, particularly Ascophyllum nodosum.
As an extraction solvent that may be used for extracting the seaweed polyphenol, water or an organic solvent, or a mixed solution thereof is used. Examples of the organic solvent include polar organic solvents including lower alcohols having from 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, sec-butanol, and tert-butanol, and ketones such as dimethyl ketone, methyl ethyl ketone, acetone, and methyl isobutyl ketone; and non-polar organic solvents such as methyl acetate, ethyl acetate, butyl acetate, and diethyl ether. A mixed product obtained by appropriately combining a polar organic solvent, such as those described above, and a non-polar organic solvent, such as those described above, is also usable. Examples of extraction methods usable for obtaining the extract include known methods such as immersion extraction, heat extraction, continuous extraction, and supercritical extraction. The extract may subsequently be concentrated using known methods. The obtained extract, concentrate or the like may be further purified using known methods. Examples of purification methods include ultrafiltration, adsorption resin treatment, molecule chromatography, partition chromatography, and liquid-liquid extraction. In the invention, it is preferable that the seaweed polyphenol has a lipase inhibitory activity. Examples of methods usable for preparation of the seaweed polyphenol include the method described in paragraphs [0017], [0018], and [0021] of JP-A No. 2005-170836.
From the viewpoint of the fat absorption inhibitory effect, the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of preferably from 0.0001 μg/ml to 50 μg/ml, and more preferably from 0.001 μg/ml to 10 μg/ml. In a case in which the IC50 value against lipase is 50 μg/ml or less, a more favorable inhibitory effect on fat absorption can be obtained. The half-maximal (50%) inhibitory concentration against lipase may be measured, for example, according to the method described in paragraph [0019] of JP-A No. 2005-170836. The IC50 value of the seaweed polyphenol against lipase may vary according to, for example, the method employed for extracting the extract.
As the seaweed polyphenol in the invention, a commercially available product with a desired half-maximal (50%) inhibitory concentration against lipase may be used, as appropriate. Examples of the commercially available product include “Seaweed Polyphenol” (derived from Ascophyllum nodosum, RIKEN VITAMIN Co., Ltd.).
The content of seaweed polyphenol in the composition for food varies according to the dosage form or the administration manner of the composition for food. The content of seaweed polyphenol in the composition for food is not particularly limited as long as the amount is effective in inhibiting fat absorption. In a case in which the composition for food is in solution form, the content of seaweed polyphenol in the composition for food may be set to be, for example, from 0.00001% by mass to 10% by mass, and preferably from 0.00001% by mass to 5% by mass, with respect to the total mass of the composition. In a case in which the composition for food is in solid form, the content of seaweed polyphenol in the composition for food may be set to be, for example, from 0.001% by mass to 50% by mass, preferably from 0.01% by mass to 20% by mass, and more preferably from 0.1% by mass to 5% by mass, with respect to the total mass of the composition. The dose of the composition for food is not particularly limited and varies according to the dosage form or the like. In general, the dose of the composition for food in the case of single daily dosing may be from 1 mg to 500 mg, and preferably from 5 mg to 200 mg, in terms of the seaweed polyphenol dose.
The tea extract in the invention is an extract obtained from a tea plant, which is an evergreen tree of the Theaceae family. As the tea plant, both of Camellia assamica, which are cultivated in India, Sri Lanka, and south-eastern Asia, and Camellia sinensis, which are cultivated in China and Japan, are usable. The tea extract is preferably a green tea extract from the viewpoint of the effect with respect to improvement of the intestinal environment.
In general, the extraction of the tea extract is preferably conducted using water, alcohol, or a hydrous alcohol as an extraction solvent. The extraction solvent to be used is more preferably hot water, ethanol, or hydrous ethanol. The alcohol concentration in the hydrous alcohol may be set to be from 30% by mass to 90% by mass, and preferably from 40% by mass to 70% by mass, with respect to the total mass of the hydrous alcohol. Examples of methods usable for drying include, but not limited to, spray drying and freeze drying.
The tea extract preferably includes an antioxidative substance such as a polyphenol or a catechin. More specifically, the tea extract preferably inclures catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, or epigallocatechin gallate, or a combination of two or more thereof, and more preferably includes epigallocatechin gallate.
The content of tea extract in the composition for food varies according to the dosage form or the administration manner of the composition for food, and is not particularly limited. The content of tea extract in the composition for food may be any content which can improve the intestinal environment in relation to the seaweed polyphenol. In a case in which the composition for food is in solution form, the content of tea extract in the composition for food may be set to 0.0001% by mass to 20% by mass, and preferably 0.001% by mass to 10% by mass, with respect to the total mass of the composition. In a case in which the composition for food is in solid form, the content of tea extract in the composition for food may be set to be from 0.5% by mass to 80% by mass, preferably from 1% by mass to 70% by mass, and more preferably from 5% by mass to 30% by mass, with respect to the total mass of the composition.
In the composition for food according to the invention, the ratio of tea extract to seaweed polyphenol (tea extract/seaweed polyphenol, in terms of mass ratio) may vary according to the levels of concentration of the respective components. The ratio of tea extract/seaweed polyphenol in the composition for food may be set to be preferably from 100 to 0.01, more preferably from 80 to 0.05, still more preferably from 50 to 3, and even more preferably from 15 to 3. In a case in which the tea extract/seaweed polyphenol ratio in the composition for food is set to be 0.01 or more, a more favorable effect with respect to improvement of the intestinal environment can be produced.
The composition for food according to the invention may further include an extract of a plant of the genus Salacia. In a case in which the composition for food further includes an extract of a plant of the genus Salacia, further improvement of the intestinal environment, including bowel movement improvement and/or fecal properties, can be achieved.
The plant of the genus Salacia is a plant of Celastraceae that grows wild mainly in Sri Lanka, India, and south-eastern Asia, and the plant is more specifically at least one plant selected from the group consisting of Salacia reticulata, Salacia oblonga, Salacia prinoides, and Salacia chinensis. Examples of the extract of a plant of the genus Salacia that may be contained in the composition for food include an extract obtained by extraction from a pulverized product of the whole plant body of a plant of the genus Salacia, and an extract (preferably, an extract powder) obtained from a portion, such as a root, a trunk, a leaf, a flower or a fruit, of the plant. It is also contemplated that one or more portions of the plant may be mixed and used. The extract of a plant of the genus Salacia for use is more preferably an extract obtained by extraction from a root or a trunk.
In a case in which an extract of a plant of the genus Salacia is used, the extract is preferably an extract obtained by drying a product which in turn is obtained from the whole plant or any of the portions of the plant by extraction with a solvent. The extraction solvent may be selected from water, an alcohol such as methanol or ethanol, or a mixed solvent of water with an alcohol or ketone such as acetone. The extraction solvent to be used is preferably water, an alcohol, or a hydrous alcohol. The extraction solvent to be used is more preferably hot water, ethanol, or hydrous ethanol. The alcohol concentration in the hydrous alcohol may be set to be from 30% v/v to 90% v/v, and preferably from 40% v/v to 70% v/v. Examples of drying methods include, but not limited to, spray drying and freeze drying.
The extract of a plant of the genus Salacia according to the invention preferably has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 2,000 μg/ml or less. A half-maximal (50%) inhibitory concentration of the extract of a plant of the genus Salacia against sucrase of 2,000 μg/ml or less ensures an increase in the number of beneficial intestinal bacteria such as bacteria of the genus Bifidobacterium (sometimes simply referred to as “bifidobacteria”), and enables the intestinal environment to be more improved. The half-maximal (50%) inhibitory concentration against sucrase may be set to be preferably from 0.001 μg/ml to 1,500 μg/ml, more preferably from 0.05 μg/ml to 1,000 μg/ml, and still more preferably from 0.05 μg/ml to 800 μg/ml. The half-maximal (50%) inhibitory concentration against sucrase may be measured according to the method described in paragraphs [0009] to [0012] of JP-A No. 2009-249315.
The composition for food according to the invention may further include a component, other than the above-described components, that can improve the intestinal environment. Examples of the component that improves the intestinal environment include yoghurt and oligosaccharide.
The composition for food according to the invention may further include at least one selected from the group consisting of calcium carbonate and silicon dioxide. The inclusion of such a substance can prevent discoloration over time of components contained in the composition for food. In particular, in a case in which the composition for food contains an extract of a plant of the genus Salacia, the inclusion can prevent discoloration over time of the extract of a plant of the genus Salacia. The silicon dioxide is preferably fine silicone dioxide in powder form.
The content of calcium carbonate or silicon dioxide in the composition varies according to the dosage form of the composition. In a case in which the dosage form for the composition is a tablet or a hard capsule, the content of calcium carbonate is preferably from 0.1% by mass to 10% by mass with respect to the composition, and the content of silicon dioxide is preferably from 0.5% by mass to 20% by mass with respect to the composition. In a case in which calcium carbonate and silicon dioxide are used in combination, they may be used at a ratio of calcium carbonate to silicon dioxide in a range of from 1:0.05 to 1:200 in terms of mass ratio.
The composition for food according to the invention may include, besides the above-described components, a carrier acceptable for food applications or a publicly-known or well-known additive agent.
Examples of a carrier preferably used for formulating the composition to have a solution form include aqueous media such as water. Examples of an additive preferably used for formulating the composition to have a solid form include excipients such as crystalline cellulose and magnesium stearate, and swelling agents such as cornstarch and alginic acid. Furthermore, shellac, sugar, a film coating base material, Yeast wrap or the like may be used as a coating agent for tablets, capsules, or granules.
In addition, low hygroscopic raw materials and moisture absorbents usable as foods or food additives may be used. Preferable examples of usable low hygroscopic raw materials include cellulose, crystalline cellulose, cellulose powder, microcrystalline cellulose, lactose, a sugar alcohol, trehalose, magnesium stearate, and calcium stearate. Examples of usable moisture absorbents include silicates, magnesium carbonate, ferrocyanides, and polysaccharides. More preferable examples of usable low hygroscopic raw materials include crystalline cellulose, microcrystalline cellulose, and lactose, and a combination of two or more thereof.
Examples of a compound required for shaping into a powder form, a solid form, or a liquid form include erythritol, maltitol, hydroxypropylcellulose, kaolin, and talc.
A black oolong tea polyphenol, an onion peel extract, a red wine polyphenol, a coffee bean manno-oligosaccharide, Orlistat, a star fruit extract, a wheat extract or the like may further be used as another fat absorption inhibiting component.
The composition for food according to the invention may be formulated into any of the liquid, solid, powder, and gel forms, and may be formulated into a form such as a solution, a tablet, a capsule (hard capsule, soft capsule) or a granule. It is preferable to formulate the composition for food into a tablet or a capsule from the viewpoint of convenience in use.
The fat absorption inhibitor according to the invention includes a seaweed polyphenol and a tea extract. Due to the combined inclusion of a seaweed polyphenol and a tea extract, the fat absorption inhibitor can inhibit fat absorption without deteriorating the intestinal environment, as descried above. The fat absorption inhibitor may further include an extract of a plant of the genus Salacia. The inclusion of an extract of a plant of the genus Salacia enables improvement of bowel movement, fecal properties, and the like.
With regard to the preparation of the seaweed polyphenol, the tea extract, and the extract of a plant of the genus Salacia for use in the fat absorption inhibitor according to the invention, the respective contents of these components in the fat absorption inhibitor, the dosage form of the fat absorption inhibitor, and the like, the same specifics as those described for the composition for food shall apply.
The manner of administering the fat absorption inhibitor according to the invention is preferably oral administration, but may be parenteral administration such as rectal administration or sublingual administration.
In one embodiment of the invention, a method of inhibiting fat absorption is provided which includes administrating a fat absorption inhibitor that includes a seaweed polyphenol and a tea extract to a subject in need of inhibition of fat absorption. Using this method, the absorption of fat into the body can be inhibited without deteriorating the intestinal environment. Examples of the subject to which the fat absorption inhibitor is administered include a mammal such as human.
In another embodiment of the invention, use of a seaweed polyphenol and a tea extract in the manufacture of a fat absorption inhibitor, and use of a seaweed polyphenol, a tea extract, and an extract of a plant of the genus Salacia in the manufacture of a fat absorption inhibitor, are also provided.
The composition for food and the fat absorption inhibitor according to the invention can inhibit fat absorption without deteriorating the intestinal environment. Therefore, the composition for food and the fat absorption inhibitor are expected to ameliorate life-style related diseases or obesity, and to exert effect with respect to the prevention or treatment of various symptoms or diseases associated with aging. Furthermore, the composition for food and the fat absorption inhibitor are expected to also exert effects with respect to weight loss, a decrease in body fat percentage, or the like.
EXAMPLES
Hereinafter, the invention is described in detail with reference to examples. However, the invention is not limited to these examples. Here, “%” is based on mass unless otherwise specified.
Examples 1 to 4 and Comparative Examples 1 to 4
The following tests were conducted in order to clarify the effect of a seaweed polyphenol and a tea extract on the intestinal environment.
40 male adults (from age 20 to age 60) were randomly divided into 8 groups each consisting of 5 people. Ingestion test was carried out for one week with respect to the samples designated for the respective groups (Examples 1 to 4 and Comparative Examples 1 to 4). The ingestion was performed by dividing the following one-day dose into three doses and having this ingested. After the intake of the sample, the questionnaire survey on abdominal symptom and fecal properties was carried out. The results are shown in Table 1. In the table, the number of the blend ratio of each component represents a percentage by mass. Here, the amount of the seaweed polyphenol ingested per day was set to 20 mg.
The components used were as follows.
Seaweed polyphenol: a product manufactured by RIKEN VITAMIN Co., Ltd., having an IC50 value against lipase of 0.01 μg/ml or less
Green tea extract: a commercial product
Extract of a plant of the genus Salacia: a Salacia reticulata extract having an IC50 value against sucrase of 200 μg/ml or less
IC50 value of the extract of a plant of the genus Salacia against sucrase and IC50 value of each sample against lipase were determined as follows.
(1) Measurement of IC50 value against sucrase
Preparation of sample solution: 2 mg of the extract of the plant of the genus Salacia was weighed out and put in a tube. 2 mL of water was added thereto, and the resultant mixture was thoroughly suspended to prepare a sample solution having a concentration of 1 mg/mL. The obtained sample solution was diluted with water to varied concentrations of 0, 50, 100, 250, and 500 μg/mL.
Preparation of substrate solution: Sucrose was dissolved in a 0.2 M maleate buffer (pH 6.0) to a sucrose concentration of 100 mM, and the resultant solution was used as a substrate solution.
Preparation of crude enzyme solution: 1 g of intestinal acetone powder rat (manufactured by Sigma-Aldrich Co. LLC.) was suspended in 10 mL of physiological saline, and then the resultant suspension was subjected to centrifugation (3,000 rpm, 4° C., 5 min) The resulting supernatant was separated, and used as a crude enzyme solution.
400 μL of the substrate solution was added to 500 μL each of the above-described sample solutions having the varied concentrations, and the solutions were pre-heated in a water bath at 37° C. for 5 minutes. 100 μL of the crude enzyme solution was added to each of the solutions, and a reaction was allowed to proceed at 37° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated by heating at 95° C. for 2 minutes, thereby terminating the reaction. The concentration of glucose produced was quantitatively determined using a commercially available GLUCOSE CII TEST WAKO kit based on the mutarotase glucose oxidase method (Wako Pure Chemical Industries, Ltd).
Preparation of blank: To 250 μL each of the above-described sample solutions having the varied concentrations, 200 μL of the substrate solution and 50 μL of the crude enzyme solution were added, and the solutions were heated at 95° C. for 2 minutes immediately after the addition of the crude enzyme solution, thereby thermally inactivating the enzyme and obtaining blank data. A calibration curve was obtained based on the obtained values, and a concentration at which the enzyme activity is inhibited by 50% (IC50 value) was determined.
(2) Measurement of IC50 Value Against Lipase
Preparation of sample solution: 2 mg of the composition for food (Examples 1 to 4, Comparative Examples 1 to 4) was weighed out and put in a tube. 2 mL of water was added thereto, and the resultant mixture was thoroughly suspended to prepare a sample solution having a concentration of 1 mg/mL. The obtained sample solution was diluted with water to varied concentrations of 0, 50, 100, 250, and 500 μg/mL.
Preparation of lipase solution: Lipase from porcine pancreas (Sigma-Aldrich Co. LLC.) was diluted with ultrapure water to prepare a solution having a concentration of 0.1 mg/mL.
Preparation of measurement sample: 10 μL of the lipase solution was added to 100 μL of the sample solution, followed by thorough mixing.
Measurement: Lipase inhibitory activity was quantified using a LIPASE KIT S (DS Pharma Biomedical Co., Ltd.).
The IC50 values of the obtained samples against lipase are indicated in Table 1 as relative values with the IC50 value of Comparative Example 1 being designated as 1.
The values regarding the abdominal symptom and the fecal properties based on the results of questionnaire survey are as follows.
(1) sensation of abdominal bloating: average of evaluations made by five people with respect to the following:
Not felt: sensation of bloating due to gas generation in the abdomen or the like was not felt;
Moderately felt: sensation of bloating in the abdomen was moderately felt;
Clearly felt: sensation of bloating due to gas generation in the abdomen or the like was clearly felt.
(2) bowel movement: the number of people who did not suffer from constipation or who did not feel a sense of incomplete evacuation after defecation.
(3) fecal properties:
Normal: slightly brownish-ocher colored feces; it required a certain period of time for the feces to collapse when the feces immersed in water after defecation.
Good: ocher colored feces; it took a shorter time for the feces to collapse when immersed in water after defecation, than that in the case of the feces evaluated as “Normal”.
Bad: brown colored feces; it took a longer time for the feces to collapse when immersed in water after defecation, than that in the case of the feces evaluated as “Normal”.
TABLE 1
Comp. Comp. Comp. Comp.
Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 1 Ex. 2 Ex. 3 Ex. 4
Seaweed polyphenol (% by mass) 2 2 2 2 2 2 2 2
Green tea extract (% by mass) 15  15  15  15 
Extract of plant of genus Salacia (% by mass) 25  25 
Yogurt (% by mass) 15  15 
Oligosaccharide (% by mass) 15  15 
Water balance balance balance balance balance balance balance balance
Abdominal symptom
Sensation of abdominal bloating Not felt Not felt Not felt Not felt Clearly Moderately Clearly Clearly
felt felt felt felt
Bowel movement 3 5 3 4 0 3 2 2
Fecal properties Normal Good Normal Normal Bad Normal Bad Bad
IC50 value of lipase 1 1   0.8 1 1 1   0.8 1
Ex.: Example;
Comp. Ex.: Comparative Example
As shown in Table 1, in the cases of the compositions according to Examples 1 to 4, each of which includes a seaweed polyphenol and a green tea extract, sensation of abdominal bloating was not felt, and favorable bowel movement was achieved. In contrast, in the case of Comparative Example 1, in which only a seaweed polyphenol was included, there was a tendency toward sensation of abdominal bloating, deteriorated bowel movement, and constipation. In Comparative Examples 2 to 4, in which an extract of a plant of the genus Salacia, yogurt, or an oligosaccharide was added, instead of the tea extract, to a seaweed polyphenol, the sensation of abdominal bloating was not eliminated, and bowel movement was not superior to that of Examples 1 to 4. As demonstrated above, it was found that the compositions according to Examples provide a fat absorption inhibitory effect exerted by the seaweed polyphenol, without deteriorating the intestinal environment.
As demonstrated in Table 2, it was also found that inclusion of an extract of a plant of the genus Salacia in addition to a seaweed polyphenol and a green tea extract enables further improvement of the intestinal environment in terms of bowel movement and fecal properties.
Therefore, according to the invention, fat absorption can be inhibited without deteriorating the intestinal environment.
REFERENCE EXAMPLES
The effect of an extract of a plant of the genus Salacia with respect to the proliferation of intestinal bifidobacteria (bacteria of the genus Bifidobacterium) was determined as follows.
Samples of the extract of the plant of the genus Salacia having half-maximal (50%) inhibitory concentrations (IC50 values) against sucrase ranging from 0 μg/ml to 2,000 μg/ml were prepared by appropriately mixing the extract of the plant of the genus Salacia (extract powder) and a crystalline cellulose.
Each of the samples was subjected to an ingestion test using 21 healthy adults as subjects. Feces were collected before the ingestion test and after 4 weeks of ingestion, and the ratio of bacteria of the genus Bifidobacterium therein (bifidobacteria after intake/bifidobacteria before intake) was determined using a TRFLP method. The results are indicated in Table 2. The numbers indicated in Table 2 represent relative values, assuming that the ratio of bacteria of the genus Bifidobacterium observed for a sample having an IC50 value against sucrase of 5,000 μg/ml is 1.
TABLE 2
Types of extract of plant of Relative ratio
genus Salacia (IC50 value [μg/ml]) of bifidobacteria
5000 1.0
2200 0.9
2000 1.4
800 3.3
400 4.0
200 4.2
100 4.1
As demonstrated in Table 2, it was found that extracts of the plant of the genus Salacia having IC50 values against sucrase of 2,000 μg/ml or less, particularly from 100 μg/ml to 800 μg/ml, have a high potential to proliferate bacteria of the genus Bifidobacterium, which are beneficial intestinal bacteria. Accordingly, it is understood that use of an extract of a plant of the genus Salacia having an IC50 value against sucrase of 2,000 μg/ml or less results in the proliferation of bacteria of the genus Bifidobacterium, which are beneficial intestinal bacteria, thereby improving the intestinal environment.
Examples of Formulation
Examples of the composition for food and the fat absorption inhibitor according to the invention are illustrated below. In the following formulations, the extract of the plant of the genus Salacia used in Example 2 may be used as an extract of a plant of the genus Salacia, and the seaweed polyphenol used in Example 1 may be used as seaweed polyphenol. The capsule formulation is obtained by filling a filling composition that includes the components as listed in the following formulation into the interior of a gelatin capsule film, using a conventional method.
The use of such compositions for food enables inhibition of fat absorption without deterioration of the intestinal environment.
(1) Tablet
Addition amount
Component (% by mass)
extract of plant of genus Salacia 25.0
red wine polyphenol 10.0
onion peel extract powder 6.0
green tea extract 15.0
seaweed polyphenol 2.0
chromium yeast 4.0
long pepper extract powder 1.0
red pepper powder 1.0
crystalline cellulose 30.0
sucrose fatty acid ester 2.0
lactose 1.0
calcium carbonate 1.0
silicon dioxide fine particles 2.0
(2) Capsule Formulation (Filling Composition)
Addition amount
Component (% by mass)
extract of plant of genus Salacia 25.0
red wine polyphenol 10.0
onion peel extract powder 6.0
green tea extract 15.0
seaweed polyphenol 2.0
chromium yeast 4.0
long pepper extract powder 1.0
red pepper powder 1.0
crystalline cellulose 33.0
calcium carbonate 1.0
silicon dioxide fine particles 2.0
The disclosure of Japanese Patent Application No. 2012-211331, filed Sep. 25, 2012, is incorporated herein by reference in its entirety.
All publications, patent applications, and technical standards mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent application, or technical standard was specifically and individually indicated to be incorporated by reference.

Claims (12)

The invention claimed is:
1. A beneficial bacteria proliferating composition, comprising effective amounts of: a seaweed polyphenol derived from a brown seaweed of the genus Ascophyllum, a green tea extract, and an extract of a plant of the genus Salacia, wherein:
the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of 0.01 μg/ml or lower,
the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 200 μg/ml or less,
the mass ratio of the green tea extract to the seaweed polyphenol (green tea extract/seaweed polyphenol) is from 15 to 0.05, and
the composition is in a tablet or a capsule, containing an excipient to prevent discoloration.
2. A beneficial bacteria proliferating fat absorption inhibitor comprising effective amounts of: a seaweed polyphenol derived from a brown seaweed of the genus Ascophyllum, a green tea extract, and an extract of a plant of the genus Salacia, wherein:
the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of 0.01 μg/ml or lower,
the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration of (IC50 value) against sucrase of 200 μg/ml or less,
the mass ratio of the green tea extract to the seaweed polyphenol (green tea extract/seaweed polyphenol) is from 15 to 0.05, and
the inhibitor is present in a tablet or a capsule, containing an excipient to prevent discoloration.
3. A method of inhibiting fat absorption, the method comprising administering an effective amount of the fat absorption inhibitor according to claim 2 to a subject in need of inhibition of fat absorption.
4. The method of inhibiting fat absorption according to claim 3, wherein the fat absorption inhibitor further comprises an extract of a plant of the genus Salacia.
5. The method of inhibiting fat absorption according to claim 4, wherein the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 2000 μg/ml or less.
6. The method of inhibiting fat absorption according to claim 3, wherein the seaweed polyphenol is a brown algae-derived polyphenol.
7. The method of inhibiting fat absorption according to claim 3, wherein the tea extract is a green tea extract.
8. The method of inhibiting fat absorption according to claim 3, wherein the fat absorption inhibitor is in a tablet form or capsule form.
9. A beneficial intestinal bacteria proliferating composition, comprising effective amounts of: a seaweed polyphenol derived from a brown seaweed of the genus Ascophyllum, a green tea extract, and an extract of a plant of the genus Salacia, wherein:
the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of 0.01 μg/ml or lower,
the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 200 μg/ml or less,
the mass ratio of the green tea extract to the seaweed polyphenol (green tea extract/seaweed polyphenol) is from 15 to 0.05, and
the composition is in a tablet or a capsule containing an excipient to prevent discoloration.
10. The beneficial intestinal bacteria proliferating composition according to claim 9, wherein the beneficial intestinal bacteria is bifidobacterium or lactobacillus.
11. A beneficial intestinal bacteria proliferating fat absorption inhibitor, comprising effective amounts of: a seaweed polyphenol derived from a brown seaweed of the genus Ascophyllum, a green tea extract, and an extract of a plant of the genus Salacia, wherein:
the seaweed polyphenol has a half-maximal (50%) inhibitory concentration (IC50 value) against lipase of 0.01 μg/ml or lower,
the extract of a plant of the genus Salacia has a half-maximal (50%) inhibitory concentration (IC50 value) against sucrase of 200 μg/ml or less,
the mass ratio of the green tea extract to the seaweed polyphenol (green tea extract/seaweed polyphenol) is from 15 to 0.05, and
the inhibitor is in a tablet or a capsule containing an excipient to prevent discoloration.
12. The beneficial intestinal bacteria proliferating fat absorption inhibitor according to claim 11, wherein the beneficial intestinal bacteria is bifidobacterium or lactobacillus.
US14/601,362 2012-09-25 2015-01-21 Composition for food and fat absorption inhibitor Active 2035-06-13 US10925918B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-211331 2012-09-25
JP2012211331A JP2014064505A (en) 2012-09-25 2012-09-25 Composition for food, and lipid absorption inhibitor
PCT/JP2013/072603 WO2014050390A1 (en) 2012-09-25 2013-08-23 Composition for food and fat absorption inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/072603 Continuation WO2014050390A1 (en) 2012-09-25 2013-08-23 Composition for food and fat absorption inhibitor

Publications (2)

Publication Number Publication Date
US20150132338A1 US20150132338A1 (en) 2015-05-14
US10925918B2 true US10925918B2 (en) 2021-02-23

Family

ID=50387799

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/601,362 Active 2035-06-13 US10925918B2 (en) 2012-09-25 2015-01-21 Composition for food and fat absorption inhibitor

Country Status (5)

Country Link
US (1) US10925918B2 (en)
EP (1) EP2901868B1 (en)
JP (1) JP2014064505A (en)
CN (1) CN104470376A (en)
WO (1) WO2014050390A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382951A (en) * 2014-12-06 2015-03-04 黑龙江众生生物工程有限公司 Extracting method for algal polyphenols
EP3199170B1 (en) * 2016-01-26 2021-07-28 FUJIFILM Corporation Salacia for reducing the number of intestinal bacteria, food, and pharmaceutical product thereof
CN107997159A (en) * 2017-12-25 2018-05-08 大连深蓝肽科技研发有限公司 A kind of microencapsulation seeweed polyphenol extract and preparation method thereof
CN108434177A (en) * 2018-03-30 2018-08-24 中国农业科学院烟草研究所 A kind of activity inhibitor and preparation method thereof and its in application hypoglycemic, in reducing blood lipid
CN113194743A (en) * 2018-12-05 2021-07-30 博塔医疗株式会社 Composition for improving food flavor comprising brown algae polyphenol as effective ingredient

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06166618A (en) 1991-06-07 1994-06-14 Taiyo Kagaku Co Ltd Composition for controlling intestinal function
JP2000152744A (en) 1998-11-18 2000-06-06 Shinji Tsuchiya Confectioneries and breads containing salacia oblonga and their production
JP2002326932A (en) 2001-03-02 2002-11-15 Kao Corp Body fat combustion promoter
CA2487588A1 (en) * 2002-05-31 2003-12-11 Suomen Ravitsemusinstituutti Oy Drink composition and a method for composing a drink
CA2548899A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and lipase inhibitor containing the same
WO2007125644A1 (en) 2006-04-26 2007-11-08 Ito En, Ltd. Fat absorption inhibitor
WO2009031690A2 (en) 2007-09-06 2009-03-12 Fujifilm Corporation Foodstuff comprising an extract of a plant of the genus salacia and flavonoid
JP2009137899A (en) 2007-12-07 2009-06-25 Fujifilm Corp Agent for reducing intestinal toxic bacterium and food or pharmaceutical preparation comprising the same
JP2011032171A (en) 2009-07-29 2011-02-17 Fuji Chem Ind Co Ltd Skin whitening composition
US7939559B2 (en) * 2004-07-05 2011-05-10 Suntory Holdings Limited Lipase inhibitors
JP2011173847A (en) 2010-02-25 2011-09-08 Fujifilm Corp Weight gain inhibitory composition and food containing the same
WO2012120236A1 (en) 2011-03-08 2012-09-13 Lab Attitude Nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss, comprising, as active agent, at least one extract of carrot
US20130059817A1 (en) * 2010-05-14 2013-03-07 Inqpharm Sdn Bhd Composition for reducing absorption of dietary fat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009249315A (en) 2008-04-03 2009-10-29 Fujifilm Corp Mineral absorption promoter, and iron deficiency anemia-ameliorating agent or food composition
JP2010285425A (en) * 2009-05-12 2010-12-24 Fujifilm Corp Agent for regulating composition ratio of intestinal bacterial flora

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06166618A (en) 1991-06-07 1994-06-14 Taiyo Kagaku Co Ltd Composition for controlling intestinal function
JP2000152744A (en) 1998-11-18 2000-06-06 Shinji Tsuchiya Confectioneries and breads containing salacia oblonga and their production
JP2002326932A (en) 2001-03-02 2002-11-15 Kao Corp Body fat combustion promoter
CA2487588A1 (en) * 2002-05-31 2003-12-11 Suomen Ravitsemusinstituutti Oy Drink composition and a method for composing a drink
JP2005527234A (en) 2002-05-31 2005-09-15 スオメン・ラビットセムスインスティトゥーティ・オイ Beverage composition and method for producing beverage
US20060134299A1 (en) 2002-05-31 2006-06-22 Suomen Ravitsemusinstituutti Oy Drink composition and a method for composing a drink
CA2548899A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and lipase inhibitor containing the same
JP2005170836A (en) 2003-12-10 2005-06-30 Riken Vitamin Co Ltd Marine alga extract and lipase inhibitor containing the same
EP1693084A1 (en) 2003-12-10 2006-08-23 Riken Vitamin Co., Ltd. Alga extract and lipase inhibitor containing the same
US20070053929A1 (en) 2003-12-10 2007-03-08 Katsura Funayama Marine algae extract and lipase inhibitor containing the same
US7939559B2 (en) * 2004-07-05 2011-05-10 Suntory Holdings Limited Lipase inhibitors
WO2007125644A1 (en) 2006-04-26 2007-11-08 Ito En, Ltd. Fat absorption inhibitor
US20090156662A1 (en) 2006-04-26 2009-06-18 Ito En, Ltd. Fat Absorption Inhibitor
WO2009031690A2 (en) 2007-09-06 2009-03-12 Fujifilm Corporation Foodstuff comprising an extract of a plant of the genus salacia and flavonoid
JP2009137899A (en) 2007-12-07 2009-06-25 Fujifilm Corp Agent for reducing intestinal toxic bacterium and food or pharmaceutical preparation comprising the same
US20100261784A1 (en) * 2007-12-07 2010-10-14 Fujifilm Corporation Agent for reducing intestinal toxic bacterium and food or pharmaceutical preparation comprising the same
CN101888848A (en) 2007-12-07 2010-11-17 富士胶片株式会社 Agent for reducing intestinal toxic bacterium and food or pharmaceutical preparation comprising the same
JP2011032171A (en) 2009-07-29 2011-02-17 Fuji Chem Ind Co Ltd Skin whitening composition
JP2011173847A (en) 2010-02-25 2011-09-08 Fujifilm Corp Weight gain inhibitory composition and food containing the same
US20120276081A1 (en) * 2010-02-25 2012-11-01 Fujifilm Corporation Body weight gain suppressing composition and food product comprising the same
US20130059817A1 (en) * 2010-05-14 2013-03-07 Inqpharm Sdn Bhd Composition for reducing absorption of dietary fat
WO2012120236A1 (en) 2011-03-08 2012-09-13 Lab Attitude Nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss, comprising, as active agent, at least one extract of carrot
US20140127297A1 (en) 2011-03-08 2014-05-08 Laurent Didden Nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss, comprising, as active agent, at least one extract of carrot

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Br. phycol. J., Jun. 1, 1984, vol. 19, No. 2, pp. 189-202, p. 189 "Inhibitors of mammalian digestive enzymes and polyphenols in some brown marine algae".
Chater et al. (2016) J. Appl. Phycol. 28: 1303-1313. *
Communication dated Dec. 1, 2015, issued by the Japan Patent Office in corresponding Japanese Application No. 2012-211331, 6 pages in Japanese and English.
Communication dated Feb. 19, 2016, issued by the European Patent Office in corresponding European Application No. 13842323.1.
Communication dated Jan. 10, 2017, from the Japanese Patent Office in counterpart application No. 2012-211331.
Communication dated Jun. 14, 2016, from the Japanese Patent Office in counterpart application No. 2012-211331.
Communication dated Mar. 17, 2016 from the Intellectual Property Office of the P.R.C. issued in corresponding Application No. 201380037950.5.
DATABASE GNDP [online] Mintel; "Power Bikini Lighten Dring", XP002753932
Database GNDP [Online] Mintel; Feb. 1, 2011 (Feb. 1, 2011), "Power Bikini Lighten Drink", XP-002753932, Database accession No. 1484074, 3 pages total.
Decision of Rejection, dispatched May 10, 2017, in corresponding CN Application No. 201380037950.5, 20 pages in English and Chinese.
International Search Report for PCT/JP2013/072603 dated Oct. 22, 2013, 7 pages in Japanese and English.
Kishino et al. (2006) J. Nutr. 136: 433-439. *
Notice of Opinion of First Examination, dated Aug. 25, 2015, issued in corresponding CN Application No. 201380037950.5, 19 pages in English and Chinese.
Ozaki et al. (2008) J. Nat. Prod. 71, 981-984. *
Sabu et al. (2002) J. Ethnopharmacology 83: 109-116. *
The Third Office Action, dated Sep. 14, 2016, issued in corresponding CN Application No. 201380037950.5, 30 pages in English and Chinese.
Trial Decision dated May 8, 2018, from the Japanese Patent Office in counterpart Japanese Application No. 2012-211331.
Tsuneki et al. (2004) BMC Pharmacology 4:18 (10 pages). *
Venables et al. (2008) Am. J. Clin. Nutr. 87: 778-84. *
Written Opinion for PCT/JP2013/072603 dated Oct. 22, 2013, 7 pages in Japanese and English.
Yoshikawa et al. (2002) J. Nutr. 132: 1819-1824. *
Zhang et al. (2007) Can. J. Physiol. Pharmacol. 85: 1116-1123. *

Also Published As

Publication number Publication date
WO2014050390A1 (en) 2014-04-03
US20150132338A1 (en) 2015-05-14
JP2014064505A (en) 2014-04-17
CN104470376A (en) 2015-03-25
EP2901868A4 (en) 2016-03-23
EP2901868A1 (en) 2015-08-05
EP2901868B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
US8226991B2 (en) Foodstuff comprising an extract of a plant of the genus Salacia and flavonoid
US10925918B2 (en) Composition for food and fat absorption inhibitor
JP5898825B2 (en) Intestinal harmful bacteria reducing agent, food or medicine containing the same
TW202210088A (en) Pharmaceutical composition and food composition for preventing, alleviating or treating coronavirus infection including elaeocarpus sylvestris extract as active ingredient
JP5752359B2 (en) Weight gain inhibiting composition and food containing the same
EP2187769B1 (en) Foodstuff of tablets or capsules
JP2010254594A (en) Agent for promoting proliferation of bacteroides in intestine
JP2014240431A (en) Intestinal harmful bacteria reducing agent, and food or medicine containing the same
JP2014239699A (en) Blood adiponectin amount increasing agent
JP6133005B2 (en) Primary bile acid and secondary bile acid production regulator
KR20180075763A (en) Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage
JP2010043036A (en) Saccharometabolism promoter
JP2016098184A (en) Tablet comprising extract of salacia plant and method for producing the same
KR101250198B1 (en) Composition of food components for appetite control comprising specific compounds as effective component
WO2005094858A1 (en) Antidiabetic composition
JP2014080448A (en) Agent for promoting proliferation of bacteroides in intestine
JP5798544B2 (en) Foods containing Salacia plant extracts and flavonoids
TR2022008429T2 (en) Coronavirus therapeutic agent containing elaeocarpus sylvestris extract as the active ingredient.
KR101305984B1 (en) Food for use of inhibition of alcohol uptake or suppression of liver damage due to alcohol comprising green tea extract containing catechin gallate, and gamma-polyglutamic acid
KR101321744B1 (en) Composition and food for use of inhibition of alcohol uptake or suppression of liver damage due to alcohol comprising green tea extract containing catechin gallate, and gamma-polyglutamic acid
KR20180076663A (en) Agent for improvement of Catechin absorptance on the intestinal epithelium

Legal Events

Date Code Title Description
AS Assignment

Owner name: FUJIFILM CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ODA, YURIKO;UEDA, FUMITAKA;REEL/FRAME:034771/0393

Effective date: 20141007

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY